Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace
Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more) Read more
athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Businesses: Indiana's gay discrimination is bad... 2 hr goonsquad 80
News Neighbors Walk for Awareness Sun depressionman22 1
News Merck's mumps vaccine clinical tests were total... Mar 24 Vaccines Cause ADHD 13
News The Centers for Disease Control and Prevention ... Mar 21 Albert 2
Wooden Furniture For Sale In UK Mar 20 gaweakte 1
News Transgender teenager Jazz Jennings signed to be... Mar 18 Bikash 2
S.S.D. Chemical / Solution , CASTRO X OXIDE (Mar '12) Mar 16 Dr Abdullah Saleh 10
More from around the web